Physician profile
Shelby Howard
NPI 1164190914
$1,564.89
in general payments reported to CMS, 2019-2025
19 companies · $175 in 2025
The $175 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $423 · 2023: $943 · 2024: $24.42 · 2025: $175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,141.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $517.31 | 2022-2025 | |
| Lilly USA, LLC | $163.50 | 2022-2023 | Jardiance, Emgality, Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $160.56 | 2022-2023 | Xifaxan |
| Glaxosmithkline, LLC. | $129.82 | 2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $98.83 | 2023-2025 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $92.04 | 2022-2023 | Verquvo, Pneumovax 23, Vaxneuvance |
| Bayer Healthcare Pharmaceuticals INC. | $50.43 | 2022-2023 | |
| Alnylam Pharmaceuticals INC. | $41.42 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $40.90 | 2022 | |
| Azurity Pharmaceuticals, INC. | $40.16 | 2023 | Edarbi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.55 | 2022-2023 | Synjardy, Jardiance |
| Janssen Pharmaceuticals, INC | $36.21 | 2022 | |
| Ironwood Pharmaceuticals, INC | $33.93 | 2022-2023 | Linzess |
| Amgen INC. | $30.82 | 2023 | Prolia, Evenity |
| Impel Pharmaceuticals INC. | $24.80 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $20.34 | 2022 | |
| Dexcom, INC. | $19.11 | 2023 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $17.42 | 2023 | |
| Sumitomo Pharma America, INC. | $10.74 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shelby Howard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.